Triple-Negative Breast Cancer: Clinical Benefit With Pembrolizumab Plus Imprime PGG
Steven J. O’Day, M.D., Executive Director of the Saint John’s Cancer Institute and Cancer Clinic, and Director of Providence Los Angeles Regional Research, presented at the American Association for Cancer Research Virtual Annual Meeting, which highlights the work of the best minds in research and medicine from institutions all over the world.
Dr. O’Day presented phase II results for the combination of pembrolizumab with a novel innate immune activator, Imprime PGG, as second-line treatment for patients with metastatic triple-negative breast cancer.